Home formulation
 

Keywords :   


Tag: formulation

Cosmetic Formulation

2016-09-01 09:06:09| Happi Breaking News

Tags: formulation cosmetic cosmetic formulation

 

In-Cosmetics North America Tackles Formulation Issues

2016-08-24 17:00:00| Happi Breaking News

Learn more about the newest techniques next month

Tags: north issues america north america

 
 

Ice Plant Fuels New Formulation

2016-08-12 16:00:00| Happi Breaking News

Dr. Hauschka targets mass market for OTC skin care.

Tags: ice plant formulation fuels

 

Data for Merck's Investigational Once-Daily Formulation of ISENTRESS (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation...

2016-07-22 13:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Resulted in Non-Inferior Efficacy and Safety to a Regimen Containing the Approved Twice-Daily Formulation EMA Accepts File Application, Plans Underway to Submit for Licensure to FDA This Year KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced efficacy and safety data in previously untreated adults with HIV-1 infection for the companys investigational once-daily formulation of ISENTRESS (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg), from the ongoing Phase 3 pivotal trial called ONCEMRK. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Carmen de Gourville, 267-305-4195orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the show data week

 

Anticipating The Formulation Challenges Of Complex Molecules

2016-06-07 10:29:46| drugdiscoveryonline Home Page

By Anil Kane, Executive Director, Global Head of Formulation Sciences Pharmaceutical Development Services, and Andreas Stolle, Vice President of API Process Development Services, Stephen Closs, Senior Director, Global Technical Operations If formulation problems surface late in the process of turning active pharmaceutical ingredients (APIs) into beneficial drug products, developers may have to go back and change their API production processes. In the worst cases, Phase 1 and Phase 2 trials may have to be redone. And due to the increasing complexity of today’s API molecules, formulation problems are arising with greater frequency, delaying development, and burdening developers with unanticipated and heavy costs.

Tags: complex challenges formulation molecules

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] next »